The news of patients on the trial is not shared directly with the potential patients, but it is shared with the clinicians. Positive results always help with recruitment and it is one reason trials of effective drugs tend to snowball.
I think people should temper their hopes for the patients in the early stages of this trial. While our trial is an unusual Phase 1 trial in that it includes known effective agents (doxorubicin and bisantrene), very late stage patients don't tend to respond well to anything. If you go back and look at some of the most effective anticancer drugs every developed you will find few responders at the Phase 1 stage. A good example of this was with Optivio (BMS's version of Keytruda) which had a couple of patient responses out of 50 patients in the Phase 1. This so impressed Merck that they poured billions of dollars into developing Keytruda.
RAC Price at posting:
$1.16 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)